H19 is expressed in a large percentage of bladder tumors, but not expressed
in healthy bladder tissue. The aim of this study is to define H19 optimal
transcriptional regulatory sequences in tumor cells, which can potentially
be used to control expression of a toxin gene in constructs to be used in b
ladder cancer gene therapy trials in mice and human. Transient expression a
ssays revealed that elements responsible for promoter activity are containe
d within the 85 bp upstream region. The transcriptional activity of this re
gion was strongly inhibited by the methylation of the Hpa II sites. A modes
t cell specificity is conferred by the upstream sequences. The human and mu
rine promoter activities were significantly increased by the human H19 4.1
kb enhancer sequence. The 85 bp H19 upstream region contains all the elemen
ts to interact with the enhancer. We showed that the human H19 promoter is
highly active in a murine bladder carcinoma cell line, justifying its use t
o drive the expression of a cytotoxin gene in gene therapy trials in mice.